Timing of Testosterone Level Measurements After Testosterone Replacement Therapy

Initial Monitoring Timeline

The American College of Physicians recommends that the first follow-up visit should occur at 1-2 months after initiating testosterone replacement therapy to assess treatment efficacy and consider dose adjustments if needed 1, 2
Testosterone levels should be formally tested 2-3 months after treatment initiation or after any dose change, with a strength of evidence based on clinical guidelines 2
Subsequent monitoring visits should be performed at 3-6 month intervals for the first year, then yearly thereafter, as recommended by the American Medical Association 1, 3

For intramuscular testosterone injections (cypionate or enanthate), peak serum testosterone levels occur 2-5 days post-injection, with a return to baseline by 10-14 days after injection, according to the Endocrine Society 1, 4
Injectable testosterone creates fluctuating serum testosterone levels with peaks and valleys between injections, which should be considered when interpreting blood test results 2

For standard testosterone cypionate or enanthate injections, measure levels midway between injections (typically day 5-7 for weekly injections) to accurately assess treatment efficacy, as recommended by the American Urological Association 2
Clinicians must interpret blood test results based on the interval since the most recent injection, taking into account the pharmacokinetics of the specific testosterone formulation 1, 4

Target testosterone levels should be in the mid-to-upper normal range for optimal treatment response, with dose adjustments made as needed to achieve this range, according to the American College of Cardiology 1, 3
If clinical response is suboptimal and testosterone levels are in the low-normal range, the testosterone dosage should be increased, with careful monitoring of serum testosterone levels and potential side effects 1, 2

At each follow-up visit, assess symptomatic response to treatment, voiding symptoms, and sleep apnea, as well as performing a physical examination, including a digital rectal examination, as recommended by the American Academy of Family Physicians 1, 3
Blood tests should measure serum testosterone, PSA levels, and hematocrit or hemoglobin level, with adjustments made to testosterone therapy as needed to minimize potential risks 1, 3
If hematocrit rises above the reference range, consider temporarily withholding testosterone therapy, reducing the dosage, or performing phlebotomy, according to the National Institutes of Health 1, 2

The American Urological Association and other guideline societies recommend monitoring PSA levels to detect prostate-related issues in patients undergoing testosterone replacement therapy 5, 6
Monitoring of PSA levels is crucial, as testosterone replacement therapy may occasionally convert an occult prostate cancer into a clinically apparent lesion, according to the New England Journal of Medicine 5, 6

The American Urological Association recommends performing prostate biopsy or referring to urology if PSA rises above 4.0 ng/mL 7
Consider biopsy if PSA increases by 1.0 ng/mL or more within any 12-month period, as recommended by the American Urological Association 7
If PSA rises by 0.7-0.9 ng/mL in one year, repeat PSA measurement in 3-6 months and perform biopsy if further elevation occurs, according to the American Urological Association guidelines 7

The Endocrine Society recommends monitoring PSA levels to detect prostate-related concerns, as TRT may unmask occult prostate cancer 7

The American Urological Association recommends that if PSA levels increase by 1.0 ng/mL or more within any 12-month period, a prostate biopsy should be considered 8
If PSA levels increase by 0.7-0.9 ng/mL in one year, PSA should be repeated in 3-6 months and a biopsy should be performed if further elevation occurs 8
The American Urological Association suggests that a PSA increase of more than 1.0 ng/mL during the first 6 months of treatment warrants urologic referral for possible biopsy 8
A PSA increase of more than 0.4 ng/mL per year after the first 6 months of treatment should prompt urologic referral for possible biopsy 8

The Journal of Urology recommends that serum testosterone concentration should be relatively stable over the measurement period, with ideally less than or equal to 10% variation 9
After discontinuation of GnRH agonists, testosterone may not return to normal for a median of 16.6 weeks, and testosterone levels should not be measured during this time 9

The Journal of Urology suggests that all PSA values used for monitoring should be obtained using the same assay, preferably at the same laboratory 9
PSA values should be recorded with a maximum of 2 significant digits after the decimal point, and treatment that may affect PSA should be constant during monitoring 9